Outlook Therapeutics financials
$0.6257+0.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $0.00 | $0.00 | $0.00 | — | — | $8.1M |
| Gross profit | $57.2K | $0.00 | $0.00 | $0.00 | — | — | $8.1M |
| Gross margin | 4.0% | — | — | — | — | — | 100.0% |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M | -$36.8M | -$36.3M |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M | -$48.9M | -$36.0M |
| Net margin | −4416.2% | — | — | — | — | — | −442.4% |
| Diluted EPS | $-1.79 | $-4.06 | $-4.72 | $-6.20 | $-7.00 | $-13.40 | $-39.60 |
| EBITDA | -$66.9M | -$71.6M | -$53.1M | -$62.9M | -$51.5M | -$35.8M | -$21.7M |
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M | -$31.8M | -$32.3M |
| Free cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | — | — | -$32.7M |
| Diluted shares | 34.8M | 18.5M | 12.5M | 10.6M | 7.6M | 3.6M | 0.9M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M | $12.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $29.9M | $29.4M | $35.6M | $10.9M | $11.8M | $1.0M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M | $19.7M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.7M | $17.7M | $16.8M |
| Shareholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.8M | $5.1M | $2.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology